Page 1 of 1
Ocrevus, rituximab may not slow disability progression in PPMS
Posted: Wed Oct 02, 2024 10:24 pm
by DIM
Anti-CD20 therapies like Ocrevus (ocrelizumab) and rituximab appear to be ineffective at slowing disability progression in people with primary progressive multiple sclerosis (PPMS), a form of the disease characterized by symptoms that steadily worsen over time, according to data from a real-world study in France.
https://multiplesclerosisnewstoday.com/ ... sion-ppms/
Re: Ocrevus, rituximab may not slow disability progression in PPMS
Posted: Sun Jan 12, 2025 1:37 pm
by David1949
I have a friend who has PPMS. He tried Ocrevus. He is now at EDSS 9, meaning he is bed ridden and almost completely helpless. On top of that it cost him $70,000! I also have PPMS, (EDSS 6.5 or 7) but I think I'll pass on Ocrevus.
Re: Ocrevus, rituximab may not slow disability progression in PPMS
Posted: Sun Jan 12, 2025 9:32 pm
by NHE
David1949 wrote: ↑Sun Jan 12, 2025 1:37 pm
I have a friend who has PPMS. He tried Ocrevus. He is now at EDSS 9, meaning he is bed ridden and almost completely helpless. On top of that it cost him $70,000! I also have PPMS, (EDSS 6.5 or 7) but I think I'll pass on Ocrevus.
The following data plot is from Ocrevus' Prescribing Information. It depicts a comparison of Ocrevus vs. placebo in PPMS. It's immediately apparent that the two data plots are nearly parallel. Moreover, Ocrevus claims a 24% relative reduction between the Ocrevus and placebo treatment groups. However, an analysis of the data plot reveals that there was just a 16.8% relative reduction.
